Figure 1.
Total number of exome mutations (Nmut) and clinical outcome in high-grade serous ovarian cancer.
All patients received platinum and most received taxanes in combination. A) Tumors were separated into Nmut high and low groups defined by the median Nmut across the whole cohort and compared to the rate of chemotherapy resistance. The significance of the differences was determined by Fisher’s exact test. B) The number of mutations (Nmut) for each tumor was compared in chemotherapy resistant and sensitive patients and is shown by dot plots. Median and 25-75 percentiles are indicated by horizontal lines. P-value is derived from the Wilcoxon rank-sum test. C) Kaplan-Meier analysis compared the progression-free survival (PFS) and D) overall survival (OS) between patients with high and low tumor Nmut. Patients that were progression-free or still alive at the time of last follow-up were censored (+). Numbers of patients at risk at each interval are given below the graphs. P-values are obtained by Log-rank test.
Figure 2.
Total number of exome mutations (Nmut) and clinical outcome in high-grade serous ovarian cancer with germline or somatic mutations in BRCA1 or BRCA2 (mBRCA) or with wild-type BRCA1 and BRCA2 (wtBRCA).
A) Nmut in tumors with mBRCA. Chemotherapy resistant and sensitive ovarian cancers are shown by dot plots. P-value is derived from the Wilcoxon rank-sum test. B) Nmut in tumors with wtBRCA. Chemotherapy resistant and sensitive tumors are shown with dot plots of each tumor as in Figure 1. Median and 25-75 percentiles are indicated by horizontal lines. P-value is derived from Wilcoxon rank-sum test. C) Kaplan-Meier analysis compared PFS and D) OS between patients with high and low Nmut in their mBRCA-associated tumors. E) Kaplan-Meier analysis compared PFS and F) OS in patients with high and low Nmut in their wtBRCA tumors. The median for Nmut was computed from the whole cohort of 316 tumors. In Kaplan-Meier analyses, patients that were progression-free or still alive at the time of last follow-up were censored (+). Numbers of patients at risk at each interval are given below the graphs. P-values are obtained from Log-rank test.
Figure 3.
Tumor Nmut and clinical treatment outcome in ovarian cancer patients carrying BRCA germline mutations with LOH at the BRCA loci in tumors.
A) Kaplan-Meier analysis compared PFS and B) OS between Nmut high and low ovarian cancers, all of which carried either a BRCA1 or BRCA2 germline mutation with LOH at the corresponding BRCA locus. C - F) Analysis in individual BRCA1 and BRCA2 mutation carrier groups. C) Kaplan-Meier analysis in patients with BRCA1-associated tumors comparing PFS, and D) OS. E) Kaplan-Meier analysis in patients with BRCA2-associated tumors comparing PFS, and F) OS. Nmut high and low are defined as a value above or below median Nmut of all mBRCA-associated tumors. Numbers of patients at risk at each interval are given below the graphs. P-values are calculated by log-rank test.
Figure 4.
Nmut and treatment outcome in patients with wtBRCA tumors and no residual disease after initial surgery.
Nmut high and low were defined by values above or below the median Nmut from all wtBRCA tumors in the cohort. A) Kaplan-Meier analysis compared PFS, and B) OS between tumor Nmut high and low in patients with wtBRCA tumors and no residual disease after debulking surgery. Numbers of patients at risk at each interval are given below the graphs. P-values are obtained from Log-rank test.